Clinical Policy: Zongertinib (Hernexeos)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.750 alerts
Get alerted when Policy CP.PHAR.750 changes without checking for updates manually.
Monitor payer policy activity
Medical-necessity and prior-authorization coverage for zongertinib (Hernexeos), primarily for adults with unresectable, recurrent, advanced, or metastatic nonsquamous non-small cell lung cancer with activating HER2 (ERBB2) mutations.
The prior systemic therapy requirement was removed from the FDA-approved indication and initial approval criteria to reflect the expanded indication in the prescribing information.
The ICHRA line of business was added during the 4Q 2026 annual review.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.